Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances (2022 - 2023)

Viridian Therapeutics, Inc.\DE has reported Long-Term Debt Issuances over the past 3 years, most recently at -$15.0 million for Q4 2023.

Quarterly results put Long-Term Debt Issuances at -$15.0 million for Q4 2023, down 3463.23% from a year ago — trailing twelve months through Dec 2024 was -$14.6 million (up 2.97% YoY), and the annual figure for FY2025 was $28.9 million, changed.
Long-Term Debt Issuances for Q4 2023 was -$15.0 million at Viridian Therapeutics, Inc.\DE, down from $446000.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for VRDN hit a ceiling of $446000.0 in Q4 2022 and a floor of -$15.0 million in Q4 2023.